Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
24.53 USD | +2.59% | -0.53% | -19.97% |
Financials (USD)
Sales 2024 * | 107M | Sales 2025 * | 161M | Capitalization | 2.97B |
---|---|---|---|---|---|
Net income 2024 * | -360M | Net income 2025 * | -319M | EV / Sales 2024 * | 24.8 x |
Net cash position 2024 * | 305M | Net cash position 2025 * | 157M | EV / Sales 2025 * | 17.5 x |
P/E ratio 2024 * |
-7.62
x | P/E ratio 2025 * |
-8.89
x | Employees | 525 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.52% |
Latest transcript on Arrowhead Pharmaceuticals, Inc.
1 day | -3.16% | ||
1 week | +4.18% | ||
Current month | +4.18% | ||
1 month | -3.28% | ||
3 months | -28.52% | ||
6 months | -0.17% | ||
Current year | -21.86% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 54 | 07-11-30 | |
Director of Finance/CFO | 57 | 08-12-31 | |
Peter Carignan
CTO | Chief Tech/Sci/R&D Officer | - | 22-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Douglass Given
CHM | Chairman | 71 | 10-11-22 |
Michael Perry
BRD | Director/Board Member | 64 | 11-12-18 |
Adeoye Olukotun
BRD | Director/Board Member | 79 | 20-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.40% | 0 M€ | 0.00% | - | |
0.35% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-10 | 24.53 | +2.59% | 876 112 |
24-06-07 | 23.91 | -3.16% | 1,052,135 |
24-06-06 | 24.69 | -2.18% | 1,066,465 |
24-06-05 | 25.24 | -0.20% | 1,348,655 |
24-06-04 | 25.29 | +2.72% | 1,228,321 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.86% | 2.97B | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+2.15% | 22.78B | |
-10.46% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- ARWR Stock